Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy - Reply

Inmaculada Hernandez, Vinayak Prasad, Walid F. Gellad

Research output: Contribution to journalArticle

LanguageEnglish (US)
JournalJAMA Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

T-Cell Antigen Receptor
Immunotherapy
Costs and Cost Analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy - Reply. / Hernandez, Inmaculada; Prasad, Vinayak; Gellad, Walid F.

In: JAMA Oncology, 01.01.2018.

Research output: Contribution to journalArticle

@article{98a65c5a867e4c1296d0b228b65454e9,
title = "Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy - Reply",
author = "Inmaculada Hernandez and Vinayak Prasad and Gellad, {Walid F.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1001/jamaoncol.2018.4657",
language = "English (US)",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",

}

TY - JOUR

T1 - Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy - Reply

AU - Hernandez, Inmaculada

AU - Prasad, Vinayak

AU - Gellad, Walid F.

PY - 2018/1/1

Y1 - 2018/1/1

UR - http://www.scopus.com/inward/record.url?scp=85054999133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054999133&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2018.4657

DO - 10.1001/jamaoncol.2018.4657

M3 - Article

JO - JAMA oncology

T2 - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

ER -